Marshall Wace
MNPR icon

Marshall Wace’s Monopar Therapeutics MNPR Stock Holding History

Marshall Wace’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,988
Closed -$946K – 2991
2025
Q1 		$946K Buy
+25,988
New +$936K ﹤0.01% 1806
2021
Q2 		– Sell
-9,531
Closed -$295K – 2906
2021
Q1 		$295K Buy
+9,531
New +$348K ﹤0.01% 2136

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's MNPR Position: Q2 2025 in Review

Marshall Wace sold out of Monopar Therapeutics (MNPR) in Q2 2025, closing a stake of 25,988 shares — an estimated $946K sold.

Marshall Wace first reported a position in MNPR in Q1 2021 and held it in 2 quarters. The position peaked at $946K in Q1 2025. 43 funds tracked by Wall St. Rank hold MNPR as of Q2 2025.

  • Marshall Wace reported no remaining Monopar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Marshall Wace sold 25,988 Monopar Therapeutics shares in Q2 2025, an estimated $946K.
  • Marshall Wace first reported a position in Monopar Therapeutics in Q1 2021 and held it in 2 quarters.
  • Marshall Wace's Monopar Therapeutics position peaked at $946K in Q1 2025.
  • 43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.